Comment from American Society of Ketamine Physicians, Practitioners and Psychotherapists
AnonymousSupportTrade association
Summary: Ruchir Gupta, representing the American Society of Ketamine Physicians, Psychotherapists & Practitioners, advocates for the FDA to approve intravenous racemic ketamine for the treatment of refractory complex regional pain syndrome (CRPS). The organization argues that ketamine is an off-patent generic drug with a well-characterized safety profile and sufficient evidence to address a significant unmet medical need in patients with no other approved pharmacotherapy.
RESPONSE: Nomination of Racemic Ketamine Hydrochloride (IV) for a Label Indication in Refractory Complex Regional Pain Syndrome (CRPS), With a Secondary Nomination in Refractory Chronic Neuropathic Pain
SUBMITTED ON BEHALF OF: American Society of Ketamine Physicians, Practitioners and Psychotherapists